<DOC>
	<DOC>NCT01428544</DOC>
	<brief_summary>The purpose of this post-marketing surveillance study is to collect and assess information retrospectively on safety and effectiveness of fondaparinux injection in patients with venous thromboembolism (VTE) whose body weight is 100 kilograms (kg) or more, or to whom fondaparinux was injected 10 mg/day. ("Arixtra" is a trademark of the GlaxoSmithKline group of companies.)</brief_summary>
	<brief_title>Special Drug Use Investigation (Retrospective) for ArixtraÂ® (Fondaparinux) Venous Thromboembolism Treatment (Over 100kg)</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Fondaparinux</mesh_term>
	<mesh_term>PENTA</mesh_term>
	<criteria>Patients with acute pulmonary thromboembolism or acute deep venous thrombosis Fondaparinux injection must be prescribed for the first time</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>